कंपनी का अवलोकन
Xencor, Inc. (XNCR) operates as a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of engineered antibodies specifically designed for the treatment of cancer and autoimmune diseases. The company functions within the healthcare sector, specifically under the biotechnology industry, where its primary focus is on advancing novel therapeutic candidates through clinical trials. This entity currently maintains a market capitalization of $898.40M, reports annual revenue of $125.58M, and employs a workforce of 260 individuals. These financial figures indicate that while the company holds a significant market capitalization relative to its revenue, generating a price-to-sales ratio of 7.15, it operates with a substantial cash reserve of $547.73M, suggesting a valuation driven largely by asset value and future clinical potential rather than current profitability.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month revenue of $125.58M, yet posts a net income loss of $-91,923,000 and an EBITDA of $-166,990,000, revealing a cost structure where expenses significantly outweigh revenues during the clinical development phase. This disparity is further evidenced by a free cash flow of $-39,165,124, which indicates that the company is burning cash to fund operations and R&D, thereby limiting its immediate financial flexibility without external capital raises. The margin profile is notably negative, with a gross margin of -90.7%, an operating margin of -189.9%, and a profit margin of -73.2%, reflecting the high cost of goods sold and operational expenditures typical of pre-revenue or late-stage clinical biotech firms. Despite these losses, the balance sheet remains robust with total cash of $547.73M against total debt of $187.75M, resulting in a debt-to-equity ratio of 29.54, which suggests a conservative leverage position relative to its cash hoard. Liquidity is exceptionally strong, as indicated by a current ratio of 6.25, meaning the company holds 6.25 times more current assets than current liabilities to cover short-term obligations. Furthermore, the return on equity stands at -14.1% and the return on assets at -12.1%, metrics that currently reflect the inability to generate accounting profits from shareholder equity or total assets, a common characteristic for clinical-stage biotechnology companies investing heavily in future growth.
मूल्यांकन आकलन
Valuation metrics for Xencor present a complex picture, with a trailing P/E ratio of N/A due to losses and a forward P/E of -4.10, which implies that the market does not expect immediate earnings turnaround and prices in a prolonged period of negative earnings. The price-to-book ratio is 1.39, indicating that the stock trades at a premium of 39% over its book value, suggesting investors are valuing the company's intangible assets and potential pipeline above its tangible net worth. Alternative valuation measures include a price-to-sales ratio of 7.15 and an EV/EBITDA of -3.22, both of which highlight that the company's enterprise value is not supported by current earnings power but rather by its revenue generation and asset base. The stock has experienced significant volatility, trading between a 52-week low of $6.92 and a 52-week high of $18.69, with the current price positioning within this wide range reflecting market sentiment on its clinical progress. Additionally, the company has a beta of 0.99, indicating that its stock price volatility mirrors the broader market movements closely, without exhibiting excessive sensitivity to general market fluctuations.
Growth & Income
Xencor, Inc. demonstrates a revenue growth rate of -46.5% year-over-year, while earnings growth is N/A due to the lack of positive earnings history, indicating that the company is currently shrinking in revenue rather than expanding its top line. The absence of earnings growth relative to revenue contraction implies that the company is facing challenges in maintaining its revenue base, likely due to the cessation or completion of certain product cycles or commercial transitions. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute profits to shareholders as it must reinvest all available capital into research, development, and clinical operations. Consequently, the overall growth and income profile is characterized by negative revenue expansion and a total reliance on internal cash reserves and external financing to sustain operations rather than generating cash flow for distribution or organic earnings growth.